Key result
Intravenous sotalol loading significantly reduced the need for dose adjustment compared with conventional oral loading (4.1% vs 16.6%; P=0.003), with no significant difference in QTc change.
Why the study?
Inpatient sotalol initiation is recommended due to proarrhythmic effects, prompting evaluation of IV sotalol loading to achieve steady state within 6 hours instead of traditional 5-dose oral titration.
Does intravenous sotalol loading improve feasibility and reduce dose adjustments compared to conventional oral loading in adult patients with atrial fibrillation?
Does intravenous sotalol loading improve feasibility and reduce dose adjustments compared to conventional oral loading in adult patients with atrial fibrillation?
Absolute Event Rate: 4.1% vs 16.6%
p-value: p=0.003
Rapid intravenous sotalol loading is a safe and feasible alternative to conventional 5-dose oral loading for atrial fibrillation, significantly reducing the need for dose adjustments and hospital costs.
IV sotalol loading appears feasible with fewer dose adjustments in AF; leaves open whether it improves safety over oral titration.
BACKGROUND: Inpatient initiation of sotalol is recommended owing to its proarrhythmic effects. OBJECTIVES: The DASH-AF (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation) trial evaluates the safety and feasibility of intravenous (IV) sotalol, achieving a steady state with maximum QTc prolongation within 6 hours instead of the traditional 5-dose inpatient oral (PO) titration. METHODS: DASH-AF is a prospective, nonrandomized, multicenter, open-label trial consisting of patients who underwent IV sotalol loading dose to initiate rapid oral therapy for atrial arrhythmias. IV dose was calculated based on the target oral dose as indicated by baseline QTc and renal function. Patients' QTc (in sinus) was measured via electrocardiography at 15-minute intervals and after IV loading completion. Patients were discharged 4 hours after first oral dose. All patients were monitored via mobile cardiac outpatient telemetry for 72 hours. The control group was composed of patients admitted for the traditional 5 PO doses. Safety outcomes were assessed in both groups. RESULTS: A total of 120 patients from 3 centers were enrolled from 2021 to 2022 in the IV loading group (compared with type of AF- and renal function-matched patients in the conventional PO loading cohort). This study demonstrated no significant change in ΔQTc in both groups, with a significantly lower number of patients requiring dose adjustment in the IV arm compared with the PO arm (4.1% vs 16.6%; P = 0.003). This led to potential cost savings of up to $3,500.68 per admission. CONCLUSIONS: The DASH-AF trial shows that rapid IV sotalol loading in atrial fibrillation/flutter patients for rhythm control is feasible and safe compared with conventional oral loading with significant cost reduction. (Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation [DASH-AF]; NCT04473807).
No takes yet. Share an insight, caveat, or question.
Lakkireddy et al. (2023) studied Atrial Fibrillation (n=120). Intravenous sotalol loading vs. Traditional 5-dose inpatient oral (PO) titration was evaluated on Patients requiring dose adjustment (p=0.003). Intravenous sotalol loading significantly reduced the need for dose adjustment compared with conventional oral loading (4.1% vs 16.6%; P=0.003), with no significant difference in QTc change.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: